[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@GerardCaelles Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::269299966.png) @GerardCaelles Gerard Caelles

Gerard Caelles posts on X about niche, $qures, $regns, approved the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::269299966/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::269299966/c:line/m:interactions.svg)

- X Week XXXXX +118%
- X Months XXXXXX +2,640%
- X Year XXXXXX -XX%

### Mentions: X [#](/creator/twitter::269299966/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::269299966/c:line/m:posts_active.svg)

- X Week X +100%
- X Months X +133%
- X Year XX -XX%

### Followers: XXXXX [#](/creator/twitter::269299966/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::269299966/c:line/m:followers.svg)

- X Months XXXXX +11%
- X Year XXXXX +7.50%

### CreatorRank: undefined [#](/creator/twitter::269299966/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::269299966/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::269299966/influence)
---

**Social category influence**
[technology brands](/list/technology-brands)  [stocks](/list/stocks) 

**Social topic influence**
[niche](/topic/niche), [$qures](/topic/$qures), [$regns](/topic/$regns), [approved](/topic/approved), [$rhhbys](/topic/$rhhbys), [$ptcts](/topic/$ptcts), [vivo](/topic/vivo), [$rrhby](/topic/$rrhby), [$nvs](/topic/$nvs), [$bmrn](/topic/$bmrn)

**Top assets mentioned**
[Novartis AG (NVS)](/topic/$nvs) [BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn) [PTC Therapeutics, Inc. (PTCT)](/topic/$ptct) [uniQure N.V. (QURE)](/topic/$qure) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt)
### Top Social Posts [#](/creator/twitter::269299966/posts)
---
Top posts by engagements in the last XX hours

"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"  
[X Link](https://x.com/GerardCaelles/status/1977771288660791721) [@GerardCaelles](/creator/x/GerardCaelles) 2025-10-13T16:19Z 1098 followers, 13.9K engagements


"Seven commercial in vivo gene therapies for rare diseases: Luxturna (RPE65-LCA2; $RRHBY) Zolgensma (SMA; $NVS) Kebilidi (AADC deficiency; $PTCT) Roctavian (HemA; $BMRN) Hemgenix (HemB; $QURE) and Elevidys (DMD; $SRPT) using AAV vectors and Vykuvek (DEB; $KRYS) using Herpesvirus. Zolgensma is a blockbuster ($1bn+ net sales/year). Elevidys was on-track to become one (strong demand) despite all the issues associated with systemic gene therapy. Luxturna has had strong demand but so few patients that the commercial case has been very challenging. Vyjuvek did $300M in revenues the first full-year"  
[X Link](https://x.com/GerardCaelles/status/1978550460983197811) [@GerardCaelles](/creator/x/GerardCaelles) 2025-10-15T19:56Z 1099 followers, XXX engagements